IGEA studies the clinical application of physical stimuli to biological systems. Our mission is to improve patients’ quality of life by developing and producing innovative, effective and safe therapeutic systems for clinical practice. IGEA develops biophysical treatments in two main areas: - Orthopedics: to improve bone healing and joint preservation. - Oncology: to treat cancer. IGEA is the world leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and electrical pulses (electroporation) applied directly to the cancer cells using specific multiple or individual electrodes. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located to the skin, subcutaneous tissue, parenchyma and bone.
| Website | https://www.igeamedical.com |
| Revenue | $13.3 million |
| Employees | 198 (73 on RocketReach) |
| Founded | 1980 |
| Industry | Medical Equipment Manufacturing |
| Keywords | Biostimulation, Medical Devices, Electrotherapy, Therapeutic Systems, Physical Therapy, Physiotherapy, Biological Systems, Patient Care, Healthcare Technology, Medical Technology, Health Tech, Biomedical Engineering, Regenerative Medicine, Innovative Therapies, Clinical Practice, Medical Research, Health Improvement, Quality Of Life |
| Competitors | Siemens Healthineers, GE HealthCare, Philips, FUJIFILM Business Innovation Asia Pacific, Hitachi, Toshiba, Elekta, Canon Medical Systems Europe, Mindray, Agfa HealthCare +42 more (view full list) |
Looking for a particular IGEA S.p.A. employee's phone or email?
The IGEA S.p.A. annual revenue was $13.3 million in 2026.
Donata Marazzi is the CEO of IGEA S.p.A..
73 people are employed at IGEA S.p.A..